PreciseDx raises $20.7M
PreciseDx, an oncology diagnostics startup, announced it raised $20.7 million in a Series B funding round.
Investment management firm Eventide Asset Management led the round. Diagnostics companies Labcorp and Quest Diagnostics participated, along with investment firm GenHenn Capital Ventures.
Related: Digital health funding: Optum Ventures, General Catalyst invest
The company uses artificial intelligence-powered technology to analyze images of pathology slides, with the goal of giving providers more information about the possible recurrence of disease.
The company will use the Series B funding for new product development focused on breast cancer diagnostics, a spokesperson said.
The funding brings PreciseDx’s total raised to $31.5 million.
Mindset Care closes $13M funding round
Mindset Care, a Social Security disability benefits-focused company, announced it secured a $13 million funding round.
The company aims to make applying for Social Security disability benefits smoother for individuals with mental illnesses and their caregivers.
Investment firm Science Inc. led the round. Asset manager Wellington Management joined venture capital firms Tubbs Ventures, Enable Ventures, XYZ and LivEdge Capital to participate in the round.
Mindset Care said it would use the funding to expand its partnerships with organizations like mental health nonprofits, government agencies and shelters.
Kaiser Permanente fund, Yale New Haven back supply chain startup
Hospital supply chain software company Clarium raised $10.5 million in a funding round.
Openwater closes $54M Series A extension
Openwater, a technology platform focused on stroke detection and treatment, announced the close of a $54 million Series A extension, bringing the round’s total to $100 million.
The platform uses multiple tools, including ultrasound and infrared imaging, to visualize and address conditions.
Singer and songwriter Peter Gabriel and venture capitalist Howard Morgan were among the round's new investors, along with venture capital firm Plum Alley Ventures.
An Openwater spokesperson declined to name a lead investor for the round. The company said in a news release the funding would be used for commercialization. Openwater is also studying how its platform can be used for patients with glioblastoma and depression.
